It is widely publicized that amyloid in the brain may not be the best agent for gauging progression and severity of Alzheimer’s disease. Tau imaging seems to hold greater promise in that arena. What does this mean for amyloid imaging?

Human epidermal growth factor receptor 2 (HER2) biomarkers have been the standard for imaging agents that target hormonally active breast cancers that tend to be very aggressive. Now researchers have developed an alternative and potentially more comprehensive biomarker of disease, HER3, according to a study presented during this week’s Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting, which was held June 7-11 in St. Louis.

An emerging radiotracer homes in on prostate-specific anatomy and finds elusive lesions, according to a study presenting this year at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

The combination of late-life depression and beta-amyloid deposition may lead to a quickening of neurodegeneration and progressive Alzheimer’s disease, according to a study presented during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting, which concludes today.

Wednesday is the last day of the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting in St. Louis, but the news and images keep coming.

NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc.  The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through NorthStar’s unique intelligent isotope separation systems, once that technology is approved by the FDA and commercially available.

Royal Philips today introduced Vereos PET/CT, the first digital PET/CT scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging  (SNMMI), taking place this week in St. Louis, Mo.  In addition to Vereos, Philips will showcase a selection of innovative, molecular imaging solutions designed to deliver outstanding image quality, critical clinical information and greater connectivity.

Society of Nuclear Medicine and Molecular Imaging (SNMMI)  leadership and a panel of experts announced today the most striking research being presented at the 2014 SNMMI Annual Meeting at the America’s Center convention center from June 7-11. This included the abstract of the year outlining how sentinel lymph node SPECT/CT imaging bests lymphoscintigraphy.